Alliance Wealth Advisors (Utah)’s Ligand Pharmaceuticals LGND Stock Holding History

Alliance Wealth Advisors (Utah)’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$560K	Buy	+1,772	New	+$418K	0.11%	120

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alliance Wealth Advisors (Utah)'s LGND Position: Q2 2026 in Review

Alliance Wealth Advisors (Utah) opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 1,772 shares worth $560K. The stake represents 0.11% of the portfolio and ranks #120 among its holdings.

417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Alliance Wealth Advisors (Utah) held 1,772 shares of Ligand Pharmaceuticals worth $560K as of Q2 2026.
Ligand Pharmaceuticals was a new Alliance Wealth Advisors (Utah) position in Q2 2026.
Ligand Pharmaceuticals made up 0.11% of Alliance Wealth Advisors (Utah)'s portfolio in Q2 2026, its #120 holding.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Alliance Wealth Advisors (Utah)'s 13F filing for Q2 2026, filed 23 Jul 2026.